# US 2023/0416350 A1 · Tau-binding antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416350 A1
- Document ID: US20230416350A1
- Status: Published application
- Kind: A1
- Application number: 18/344,945
- Filed: 2023-06-30
- Published: 2023-12-28
- Earliest claimed: 2015-07-06
- Assignees: Ucb Biopharma Srl
- Applicants: Ucb Biopharma Srl
- Inventors: DAVID EDWARD ORMONDE KNIGHT; TERENCE SEWARD BAKER; DAVID JAMES MCMILLAN; ROBERT ANTHONY GRIFFIN; GEORGES MAIRET-COELLO; PATRICK DOWNEY; JEAN-PHILIPPE COURADE
- Web page: https://patentgrep.com/patent/US20230416350A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to Tau-binding antibodies and binding fragments thereof.

## Claims

### Claim 1

An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof comprises:
a light chain variable region comprising a CDR1 selected from SEQ ID NO: 1, a CDR2 selected from SEQ ID NO: 2, and a CDR3 selected from SEQ ID NO: 3; and
a heavy chain variable region comprising a CDR1 selected from SEQ ID NO: 4, a CDR2 selected from SEQ ID NO: 5, and/or a CDR3 selected from SEQ ID NO: 6.
